About the Company
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KALA News
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA BIO (KALA) came out with a quarterly loss of ... Syros Pharmaceuticals, Inc. (SYRS), another stock in the same industry, has yet to report results for the quarter ended September 2023.
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
About KALA BIO, Inc. KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye.
KALA BIO, Inc. Common Stock (KALA)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
KALA BIO, Inc. (KALA) Stock Historical Prices & Data - Yahoo Finance
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Kala Bio Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Kala Bio Inc KALA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
KALA BIO Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...